Physician profile
Caren E Michael
NPI 1124679576
$4,062.33
in general payments reported to CMS, 2019-2025
13 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.27 · 2022: $1,068 · 2023: $921 · 2024: $1,677 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,878 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,878.26 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,128.29 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $813.84 | 2022-2025 | |
| Amgen INC. | $399.17 | 2022-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $187.85 | 2021-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $125.00 | 2022 | |
| Kaleo, INC. | $120.21 | 2023-2024 | Auvi-Q |
| Abbvie INC. | $85.34 | 2024 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $58.52 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.08 | 2024 | Cuvitru |
| Sanofi US Services INC. | $19.69 | 2025 | |
| Glaxosmithkline, LLC. | $15.20 | 2023 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caren Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.